Imaging-assisted anticancer nanotherapy
Open accessAbstract
Cancer nanomedicines are submicrometer-sized formulations designed to improve the biodistribution of anticancer drugs, resulting in less off-target localization, altered toxicity profiles, improved target site accumulation and enhanced efficacy. Together, these beneficial features have resulted in the regulatory approval of about a dozen nanomedicines for the treatment of solid and hematological malignancies. In recent years, significant progress has been made in combining nanomedicines with imaging, to better understand key aspects of the tumor-targeted drug delivery process, and to address the high inter- and intra-individual heterogeneity in the Enhanced Permeability and Retention (EPR) effect. Strategies explored in this regard have included the use of traditional imaging techniques, companion diagnostics and nanotheranostics. Preclinically, integrating imaging in nanomedicine and drug delivery research has enabled the non-invasive and quantitative assessment of nanocarrier biodistribution, target site accumulation and (triggered) drug release. Clinically, imaging has been emerging as a promising tool for patient stratification, which is urgently needed to improve the translation of cancer nanomedicines. We here summarize recent progress in imaging-assisted anticancer nanotherapy and we discuss future strategies to improve the performance of cancer nanomedicines in patients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Imaging assists in determining nanodrug distribution, target tumor site accumulation, and drug release.
“Imaging assists in determining nanodrug distribution, target tumor site accumulation, and drug release [126].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [126]
Upon intravenous injection, the FRET/Cy5.5 intensity ratio was determined to evaluate NP-drug association demonstrating Cy7-X with the polymeric matrix had the highest NP association and inhibited early drug release.
“Upon intravenous (i.v.) injection, the FRET/Cy5.5 intensity ratio was determined to evaluate NP-drug association demonstrating Cy7-X with the polymeric matrix had the highest NP association and inhibited early drug release [126].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [126]
Cy5.5-PLGA NPs and an encapsulated Cy7X model drug were utilized to investigate NP-drug association and release kinetics with in vivo optical imaging in a mouse model of the TNBC cell line MDA-MB-231.
“Cy5.5-PLGA NPs and an encapsulated Cy7X model drug was utilized to investigate the NP–drug association and release kinetics with in vivo optical imaging in a mouse model of the TNBC cell line MDA-MB-231.”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [126]
Combination of nanodrugs with imaging modalities is crucial for visualizing tumor-targeted drug delivery processes, and inter- and intraindividual heterogeneity in EPR-based drug delivery.
“The combination of nanodrugs with imaging modalities is crucial for visualizing tumor-targeted drug delivery processes, and inter- and intraindividual heterogeneity in EPR-based drug delivery [126].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 69 · Cited by 74
- Authors
- Dasgupta, A., Biancacci, I., Kiessling, F., & Lammers, T.
- Affiliations
- Universitätsklinikum Aachen (DE)
- Utrecht University (NL)
- Corresponding author
- Dasgupta, Anshuman
- Biancacci, Ilaria
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2020
- Volume
- 10
- Issue
- 3
- Pages
- 956-967
- ISSN
- 1838-7640 (ISSN-L)
- PMC
- PMC6956808
- OpenAlex
- W2992581850
- Cited by
- 74
- References
- 69
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 12 · 2023: 10 · 2022: 6 · 2021: 14 · 2020: 12
- FWCI
- 0.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Theranostics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Twente Research Information (publishedVersion, cc-by)
- RWTH Publications (RWTH Aachen) (submittedVersion, other-oa)
- University of Twente Research Information (submittedVersion, cc-by)
- Funders
- European Commission (NSC4DIPG, EuroNanoMed-III: NSC4DIPG)
- National Science Council
- FP7 Ideas: European Research Council (309495)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Engineering › Biomedical Engineering › Nanotechnology research and applications
- Keywords
- cancer nanomedicine, nanotheranostics, enhanced permeability and retention effect, tumor heterogeneity, triggered drug release, companion diagnostics, patient stratification
- MeSH terms
- Theranostic Nanomedicine, Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Delivery Systems, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
